H
Humacyte, Inc. (HUMA)
NMS – Real Time Price. Currency in USD
0.65
-0.06 (-8.13%)
Market open: Aug 12, 2026, 1:48 PM EDT
0.70
-0.01 (-1.41%)
Previous after-hours: Aug 11, 2026, 7:46 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
0.65
-0.06 (-8.13%)
Market open: Aug 12, 2026, 1:48 PM EDT
0.70
-0.01 (-1.41%)
Previous after-hours: Aug 11, 2026, 7:46 PM EDT
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
| Name | Position |
|---|---|
| Dr. Heather Connelly Ph.D. | Chief Quality & Regulatory Officer |
| Dr. Laura E. Niklason M.D., Ph.D. | Founder, President, CEO & Director |
| Dr. Shamik J. Parikh M.D. | Chief Medical Officer |
| Dr. Todd E. Rasmussen M.D. | Chief Surgical Officer |
| Mr. Dale A. Sander | CFO, Chief Corporate Development Officer & Treasurer |
| Mr. Jim Mercadante | Chief Commercial Officer |
| Mr. Rick McElheny | Senior Vice President of Business Development |
| Ms. Lisa Molyneux | Chief Strategy Officer |
| Ms. Sabrina Osborne GPHR, SPHR | Chief People Officer |
| Date | Type | Document |
|---|---|---|
| 2026-07-31 | 8-K | tm2621850d1_8k.htm |
| 2026-06-11 | 8-K | tm2617224d2_8k.htm |
| 2026-06-10 | 8-K | tm2617224d1_8k.htm |
| 2026-06-09 | 8-K | tm2617355d1_8k.htm |
| 2026-06-05 | 8-K | tm2616944d2_8k.htm |
| 2026-05-14 | S-8 | tm2614662d1_s8.htm |
| 2026-05-13 | 10-Q | huma-20260331.htm |
| 2026-05-08 | 8-K | tm2614071d1_8k.htm |
| 2026-04-28 | DEF 14A | huma-20260428.htm |
| 2026-04-24 | 8-K | tm2612631d1_8k.htm |